107 results
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd
25 Apr 24
Report of Foreign Private Issuer
4:00pm
ADDRESSING LARGE MARKETS WITH UNDERSERVED NEEDS Common diseases (e.g. COVID - 19, Influenza) Platform potential for response to emerging pandemic pathogens
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd
18 Jan 24
Report of Foreign Private Issuer
11:50am
- 19, Influenza) Platform potential for response to emerging pandemic pathogens Atopic Dermatitis $9.2B Source: GlobalData, 7 major markets (US, 5EU
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd
9 Jan 24
Report of Foreign Private Issuer
8:45am
- 19, Influenza) Platform potential for response to emerging pandemic pathogens Atopic Dermatitis $9.2B Source: GlobalData, 7 major markets (US, 5EU
10-K
2022 FY
SCNI
Scinai Immunotherapeutics Ltd
17 Apr 23
Annual report
4:06pm
into 2031, with the exception of a temporary suspension of the payment reduction from May 1, 2020 through December 31, 2021 due to the COVID-19 pandemic … . If the COVID-19 pandemic subsides or the COVID-19 disease does not evolve into a seasonally recurrent disease, it may reduce demand for our Covid-19
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd
29 Dec 22
Report of Foreign Private Issuer
10:39am
on attractive terms, if at all ; risks relating to the COVID - 19 (coronavirus) pandemic ; BiondVax’s ability to acquire rights to additional product
6-K
EX-99.1
9w9kwbxi2bv2uqosi3qm
20 Dec 22
BiondVax Announces Closing of $8 Million Underwritten Public Offering
5:29pm
424B4
shkcz
20 Dec 22
Prospectus supplement with pricing info
11:59am
6-K
EX-99.1
2o2e h4zvnn7mtmhsu
19 Dec 22
BiondVax Announces Pricing of $8 Million Underwritten Public Offering
6:02am
6-K
EX-99.1
zmgfzxsg6mj3mqej
14 Dec 22
Report of Foreign Private Issuer
9:11am
F-1/A
ku4y70x us8fgd1rp3
12 Dec 22
Registration statement (foreign) (amended)
5:25pm
6-K
EX-99.1
0nslgup 75h8rve
30 Nov 22
BiondVax announces Third Quarter 2022 Financial Results and Provides Business Update
2:41pm
6-K
EX-99.1
11z j3tss
29 Nov 22
BiondVax reports successful results in preclinical in vivo study of its innovative inhaled COVID-19 NanoAb therapy
11:09am
6-K
EX-99.1
9uxs28mn1t 6cn7
8 Nov 22
1 RAFT meeting | 6 - 9 NOVEMBER 2022 Dalit Weinstein - Fischer
4:53pm
6-K
EX-99.1
56048 mx0v0xlko
3 Oct 22
BiondVax announces financial plans to support its ongoing NanoAb pipeline development
4:05pm
F-1
fyszc 36t9
29 Sep 22
Registration statement (foreign)
9:22am
6-K
EX-99.1
xx3p agkkxwgjuml
21 Sep 22
Report of Foreign Private Issuer
6:04am
6-K/A
EX-99.1
bygszt0mqqunrk
29 Aug 22
BiondVax announces Second Quarter 2022 Financial Results and Provides Business Update
4:51pm
6-K
EX-99.1
poe 9hxuz
25 Aug 22
BiondVax announces Second Quarter 2022 Financial Results and Provides Business Update
4:02pm
6-K
EX-99.1
60ey 8o1246
10 Aug 22
Report of Foreign Private Issuer
9:05am
6-K
EX-99.1
62jafc3
8 Jun 22
BiondVax receives supportive Scientific Advice from the Paul Ehrlich
6:27am